Search

Displaying results 4091 - 4100 of 10000 in total
  1. Drug

    Diaziquone

    go.drugbank.com/drugs/DB17174
    Experimental

    Categories: Compounds used in a research, industrial, or household setting
  2. Drug

    Phosphocysteamine

    go.drugbank.com/drugs/DB17640
    Experimental

    Categories: Compounds used in a research, industrial, or household setting
  3. Drug

    Zanapezil

    go.drugbank.com/drugs/DB04859
    Experimental

    Zanapezil (TAK-147) is a selective acetylcholine (ACh) esterase inhibitor under investigation as a drug for Alzheimer's disease (AD) treatment.

  4. Drug

    EP-2104R

    go.drugbank.com/drugs/DB05675
    Experimental

    It is being developed by EPIX Pharmaceuticals, Inc. … EP-2104R is an imaging pharmaceutical under development for the detection of blood clots. It is the first targeted high-resolution technique designed to visualize blood clots directly.

  5. Drug

    Imexon

    go.drugbank.com/drugs/DB05003
    Investigational

    Imexon is currently being studied for the treatment of pancreatic, lung, breast, prostate, melanoma, and multiple myeloma cancers. It belongs to the family of drugs called cyanoaziridine derivatives. … Imexon is a cyanoaziridine derivative. Imexon is a thiol-binding small molecule which induces mitochondrial oxidation, a loss of membrane potential and cytochrome C, leading to apoptosis.

  6. Drug

    Smilagenin

    go.drugbank.com/drugs/DB05450
    Investigational

    in Parkinson’s disease. … P58 is a protein synthesis stimulant acts by restoring levels of proteins that are altered in the ageing brain, reversing the loss of nerve receptors in the ageing brain and potentially allowing for the

  7. Drug

    Sulfamethazine

    go.drugbank.com/drugs/DB01582
    ApprovedVet approvedWithdrawn

    It has a spectrum of antimicrobial action similar to other sulfonamides.

    Synonyms: N-(4,6-Dimethyl-2-pyrimidyl)sulfanilamide, N(1)-(4,6-Dimethyl-2-pyrimidyl)sulfanilamide
  8. Drug

    LY2275796

    go.drugbank.com/drugs/DB05165
    Investigational

    LY2275796 targets eukaryotic initiation factor- 4E (eIF-4E), a protein involved in the translation of key growth and survival factors that drive tumor progression, angiogenesis and metastases. … LY2275796 is a second-generation antisense anti-cancer drug candidate for clinical development.

  9. Drug

    NXN-188

    go.drugbank.com/drugs/DB06096
    Investigational

    NXN-188 is a first-in-class, dual-action small molecule incorporating both neuronal nitric oxide synthase (nNOS) inhibition and 5-HT agonism that is being developed for the treatment of acute migraine.

  10. Drug

    Sirna-027

    go.drugbank.com/drugs/DB05896
    Investigational

    It is used to treat Macular degeneration. … VEGFR-1 is a key component of the clinically validated vascular endothelial growth factor (VEGF) pathway. Sirna-027 is developed by Sirna Therapeutics and is under the phase I of clinical trails.